Ann: Opthea Completes COAST Final Week 52 Patient Visit, page-13

No, the stock is not worth $10B today. The point is that it could be worth $10B or more if trials are successful and the drug is commercialized (FY26/27). It’s a global market hungry for improvements in vision for nAMD.

Remember, any investment in OPT could result in 85% or more losses if the trials fail. So, you have to balance risk / reward. Obviously, anyone investing today needs to understand those risks.From my point of view, even if P3 were a coin toss with 50/50 odds, the stock is still undervalued at today's price. You might do your own analysis and hypothetically conclude that the probability of success is only 30%, making $1 a fair value on a discounted cash flow basis and that’s fine.

Nice to see others perspectives.